Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST®

December 10, 2020 at 12:00 AM EST
Pharming Group announces that the first patient has been enrolled in a randomised, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalised with confirmed COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the United States.